USPTO Examiner BERTAGNA ANGELA MARIE - Art Unit 1637

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
16972738CLEAVABLE CO-OPERATIVE PRIMERS AND METHOD OF AMPLIFYING NUCLEIC ACID SEQUENCES USING SAMEDecember 2020October 2023Abandon3401NoNo
16975542METHOD FOR PRIMER EXTENSION REACTION WITH IMPROVED SPECIFICITYNovember 2020October 2023Abandon3701NoNo
17099093Method for Identifying Gene Fusions by Circle cDNA AmplificationNovember 2020June 2023Allow3120YesNo
17080813METHODS OF ANALYSIS OF METHYLATIONOctober 2020November 2023Abandon3601NoNo
17038412SMALL RNA DETECTION METHOD BASED ON SMALL RNA PRIMED XENOSENSOR MODULE AMPLIFICATIONSeptember 2020November 2022Allow2511YesNo
17032414GENE RELEVANT TO PAPILLARY THYROID TUMORSSeptember 2020July 2023Abandon3321NoNo
16927353METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTSJuly 2020October 2024Abandon5121NoNo
16959983ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY MINOR GROOVE BINDING MOIETIESJuly 2020April 2024Abandon4631NoNo
16919238METHODS OF NUCLEIC ACID SAMPLE PREPARATIONJuly 2020July 2023Allow3611NoNo
16958797PAPER-BASED COLORIMETRIC SENSOR KIT FOR QUICKLY AND SIMPLY DIAGNOSING MERCURY IN SITU WITH NAKED EYE AND METHOD FOR QUICKLY AND SIMPLY DETECTING MERCURY IN SITU WITH NAKED EYE USING THE SAMEJune 2020July 2022Allow2520NoNo
16906165METHODS AND COMPOSITIONS FOR SIZE-CONTROLLED HOMOPOLYMER TAILING OF SUBSTRATE POLYNUCLEOTIDES BY A NUCLEIC ACID POLYMERASEJune 2020May 2021Allow1010YesNo
16956552IMPROVEMENTS IN OR RELATING TO AMPLIFICATION OF NUCLEIC ACIDSJune 2020June 2022Allow2420NoNo
16897588METHODS FOR DETERMINING A NUCLEOTIDE SEQUENCE CONTIGUOUS TO A KNOWN TARGET NUCLEOTIDE SEQUENCEJune 2020December 2022Allow3020YesNo
16769229Compositions and Methods for Detecting Toxigenic Clostridium DifficileJune 2020June 2024Allow4823YesNo
16768356METHOD FOR AMPLIFYING TARGET NUCLEIC ACID AND COMPOSITION FOR AMPLIFYING TARGET NUCLEIC ACIDMay 2020December 2022Allow3121NoNo
16849344Single Cell Genomic Sequencing Using Hydrogel Based DropletsApril 2020May 2021Allow1331YesNo
16804695METHODS OF NUCLEIC ACID SAMPLE PREPARATION FOR ANALYSIS OF DNAFebruary 2020February 2022Allow2411NoNo
16803731A NANOSTRUCTURE, A BIOSENSOR INCLUDING THE NANOSTRUCTURE, AND A SCREENING METHODFebruary 2020January 2023Allow3511NoNo
16638346DIGITAL AMPLIFICATION WITH PRIMERS OF LIMITED NUCLEOTIDE COMPOSITIONFebruary 2020April 2023Allow3821YesNo
16751000METHOD FOR INCREASING POLYMERASE PROCESSIVITYJanuary 2020April 2022Abandon2701NoNo
16735372POLYNUCLEOTIDE AMPLIFICATION USING CRISPR-CAS SYSTEMSJanuary 2020April 2024Allow5121NoNo
16619999METHOD FOR DIAGNOSING ATOPIC DERMATITIS THROUGH MICROBIAL METAGENOMIC ANALYSISDecember 2019August 2023Abandon4422YesNo
16700493CAPTURE OF NUCLEIC ACIDS USING A NUCLEIC ACID-GUIDED NUCLEASE-BASED SYSTEMDecember 2019February 2023Abandon3821NoYes
16667092BORDETELLA DETECTION ASSAYOctober 2019July 2022Allow3210NoNo
16605367SWITCH-LIKE ISOTHERMAL DNA AMPLIFICATION DEMONSTRATING A NON-LINEAR AMPLIFICATION RATEOctober 2019May 2024Abandon5521NoNo
16601204DETECTION OF SEQUENCES UNIQUELY ASSOCIATED WITH A DNA TARGET REGIONOctober 2019November 2020Allow1321NoNo
16581129Method for Blocking miRNASeptember 2019June 2023Allow4421YesNo
16576583METHODS AND COMPOSITIONS FOR DNA PROFILINGSeptember 2019July 2022Allow3421NoNo
16543963DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN BIOLOGICAL SAMPLESAugust 2019January 2023Allow4130YesNo
16484192COMPOSITION FOR POLYMERASE REACTIONAugust 2019April 2023Allow4421YesNo
16533444DILUTION TAGGING FOR QUANTIFICATION OF BIOLOGICAL TARGETSAugust 2019April 2024Allow5641YesNo
16528222METHODS OF ANALYSIS OF METHYLATIONJuly 2019September 2020Allow1321NoNo
16511304METHODS OF REDUCING DENSITY-DEPENDENT GC BIAS IN AMPLIFICATIONJuly 2019July 2020Allow1311YesNo
16455828METHOD AND SYSTEM FOR SUBSTANCE DETECTION WITH A MAGNETIC SENSORJune 2019July 2023Abandon4841YesNo
16431039GENETIC ARRAY FOR SIMULTANEOUS DETECTION OF MULTIPLE SALMONELLA SEROVARSJune 2019July 2022Allow3821YesNo
16412353METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCIMay 2019November 2019Abandon601NoNo
16411770METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGMay 2019December 2021Allow3132YesNo
16412043METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGMay 2019December 2021Allow3132YesNo
16411585SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBERMay 2019July 2020Abandon1420YesNo
16411677METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGMay 2019November 2020Abandon1821NoNo
16401535METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGMay 2019October 2019Abandon601NoNo
16399911SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBERApril 2019October 2020Abandon1820YesYes
16399794METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGApril 2019December 2020Abandon1921NoNo
16395154METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGApril 2019December 2020Abandon2021NoNo
16383279INCREASED SIGNAL TO NOISE IN NUCLEIC ACID SEQUENCINGApril 2019January 2022Allow3311YesNo
16360843METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGMarch 2019July 2019Abandon400NoNo
16289049METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGFebruary 2019March 2021Abandon2521NoNo
16289528METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGFebruary 2019August 2020Abandon1811NoNo
16325247DOUBLE-STRANDED CIRCLE PROBESFebruary 2019December 2022Allow4620NoNo
16314356RNA REVERSE TRANSCRIPTION AMPLIFICATION METHODDecember 2018August 2021Abandon3110NoNo
16313750IMPROVEMENTS IN OR RELATING TO NUCLEIC ACID AMPLIFICATION PROCESSESDecember 2018December 2021Allow3621YesNo
16223053Polymerase Assay with a FRET SubstrateDecember 2018January 2021Allow2531NoNo
16210284TRANSPOSON END COMPOSITIONS AND METHODS FOR MODIFYING NUCLEIC ACIDSDecember 2018May 2021Allow2911YesNo
16209785METHOD AND KIT FOR ESTIMATING THE AMOUNT OF A METHYLATED LOCUS IN A SAMPLEDecember 2018October 2020Allow2300YesNo
16196684SYSTEMS AND METHODS FOR PREPARING NUCLEIC ACID MOLECULES FOR CHROMATIN ANALYSISNovember 2018April 2022Abandon4142YesNo
16178262Analyte Enrichment Methods and CompositionsNovember 2018November 2019Allow1310NoNo
16155771METHODS FOR GENOTYPINGOctober 2018December 2021Allow3830YesNo
16108612KITS COMPRISING NUCLEIC ACID TEMPLATES AND PRIMERS FOR USE IN PRE-AMPLIFICATION ASSAYSAugust 2018May 2021Allow3311YesNo
16078261NUCLEIC ACID SEQUENCING METHOD AND SYSTEM EMPLOYING ENHANCED DETECTION OF NUCLEOTIDE-SPECIFIC TERNARY COMPLEX FORMATIONAugust 2018January 2021Allow2911YesNo
16105057METHOD OF DESIGNING PRIMERS, METHOD OF DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs), METHOD OF DISTINGUISHING SNPs, AND RELATED PRIMERS, DETECTABLE OLIGONUCLEOTIDES, AND KITSAugust 2018November 2020Abandon2701NoNo
16036511METHODS AND COMPOSITIONS FOR ISOLATING ASYMMETRIC NUCLEIC ACID COMPLEXESJuly 2018October 2020Allow2710YesNo
16067191INDEXING BASED DEEP DNA SEQUENCING TO IDENTIFY RARE SEQUENCESJune 2018June 2020Allow2411YesNo
16021670Scavenger Compounds for Improved Sequencing-by-SynthesisJune 2018November 2020Abandon2901NoNo
16017340COMPOSITIONS AND METHODS FOR TARGETED NUCLEIC ACID SEQUENCE ENRICHMENT AND HIGH EFFICIENCY LIBRARY GENERATIONJune 2018August 2020Allow2610NoNo
16061065ISOTHERMAL AMPLIFICATION FOR THE DETECTION OF INFLUENZA VIRUSES IN A SAMPLEJune 2018February 2022Abandon4431YesNo
16001279CRUDE BIOLOGICAL DERIVATIVES COMPETENT FOR NUCLEIC ACID DETECTIONJune 2018January 2019Allow710YesNo
15990400NMR SYSTEMS AND METHODS FOR THE RAPID DETECTION OF ANALYTESMay 2018July 2020Abandon2621NoNo
15984612METHODS FOR DETERMINING A NUCLEOTIDE SEQUENCE CONTIGUOUS TO A KNOWN TARGET NUCLEOTIDE SEQUENCEMay 2018April 2020Allow2310YesNo
15976701METHOD FOR NUCLEIC ACID SEQUENCINGMay 2018October 2019Allow1700YesNo
15772865METHOD FOR EXTRACTING AND CHARACTERIZING MOLECULAR CLONESMay 2018December 2023Abandon6061NoNo
15967397METHOD FOR MEASURING TUMOR BURDEN IN PATIENT DERIVED XENOGRAFT (PDX) MICEApril 2018March 2021Allow3421NoNo
15966353LIGATION-BASED RNA AMPLIFICATIONApril 2018April 2020Allow2311YesNo
15953304METHODS AND SYSTEMS FOR NUCLEIC ACID AMPLIFICATIONApril 2018October 2020Abandon3001NoNo
15937327DEVICES, SYSTEMS AND METHODS FOR NUCLEIC ACID SEQUENCINGMarch 2018February 2021Abandon3511NoNo
15926341UNIVERSAL HAIRPIN PRIMERSMarch 2018November 2020Allow3221YesNo
15756441Method for Exploring Useful Genetic Resources Through Bulk Metagenome Analysis and Use ThereofFebruary 2018January 2022Allow4731YesNo
15905952METHODS AND KITS FOR DEPLETING UNDESIRED NUCLEIC ACIDSFebruary 2018July 2022Allow5351YesNo
15907163LARGE-SCALE SYNTHESIS OF MESSENGER RNAFebruary 2018September 2022Allow5531YesNo
15754194DUMBBELL- PCR: A METHOD TO QUANTIFY SPECIFIC SMALL RNA VARIANTS WITH A SINGLE NUCLEOTIDE RESOLUTION AT TERMINAL SEQUENCESFebruary 2018August 2022Allow5431YesNo
15900942NUCLEIC ACID AMPLIFICATION METHOD PRODUCING URACIL-CONTAINING AMPLIFICATION PRODUCTSFebruary 2018October 2020Allow3211YesNo
15898460METHODS AND COMPOSITIONS FOR SIZE-CONTROLLED HOMOPOLYMER TAILING OF SUBSTRATE POLYNUCLEOTIDES BY A NUCLEIC ACID POLYMERASEFebruary 2018March 2020Allow2510YesNo
15569981Use of molecular marker DKK-3 associated with muscle atrophyFebruary 2018March 2022Allow5341YesNo
15883431HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSIONJanuary 2018August 2020Abandon3001NoNo
15881384SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBERJanuary 2018December 2018Allow1120YesNo
15881488SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBERJanuary 2018April 2019Allow1521YesNo
15877214DIRECT QUANTITATIVE PCR DEVICE AND METHOD OF USE THEREOFJanuary 2018May 2020Abandon2801NoNo
15875816SELECTIVE AMPLIFICATION USING BLOCKING OLIGONUCLEOTIDESJanuary 2018February 2022Allow4941YesNo
15864500COMPOSITIONS AND METHODS FOR DETECTING MECC-CONTAINING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUSJanuary 2018September 2018Allow810YesNo
15739672PRIMER SET FOR 1,4-DIOXANE-DEGRADING BACTERIA, AND METHOD FOR DETECTING AND QUANTIFYING 1,4-DIOXANE-DEGRADING BACTERIADecember 2017April 2019Abandon1610NoNo
15831998Lipid-polymer Hybrid Nanoparticle Biochip and Application ThereofDecember 2017March 2021Abandon3921NoNo
15825553GENE SYNTHESIS PROCESS, GENE CHIP AND KITNovember 2017November 2020Abandon3620NoNo
15816571MOLECULAR IDENTIFICATION METHOD FOR SINGLE DINOFLAGELLATE CYSTNovember 2017July 2019Allow2020YesNo
15816738HIGHLY SENSITIVE METHODS FOR DETECTING BTK RESISTANCE MUTATIONS IN RNA AND DNANovember 2017March 2021Abandon4021NoNo
15810383GENE RELEVANT TO PAPILLARY THYROID TUMORSNovember 2017January 2021Abandon3841YesNo
15809162METHOD OF DIAGNOSING NEOPLASMSNovember 2017June 2019Abandon1920NoNo
15807474PREDICTING BREAST CANCER TREATMENT OUTCOMENovember 2017September 2018Abandon1010NoNo
15805871METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGNovember 2017March 2020Abandon2941NoNo
15806047METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGNovember 2017October 2019Abandon2431NoNo
15804693Method for Studying V(D)J Combinatory DiversityNovember 2017July 2023Allow6021YesNo
15805095IDENTIFICATION OF GENE ASSOCIATED WITH READING DISABILITY AND USES THEREFORNovember 2017August 2019Abandon2110NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BERTAGNA, ANGELA MARIE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
12
Examiner Affirmed
10
(83.3%)
Examiner Reversed
2
(16.7%)
Reversal Percentile
27.9%
Lower than average

What This Means

With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
76
Allowed After Appeal Filing
6
(7.9%)
Not Allowed After Appeal Filing
70
(92.1%)
Filing Benefit Percentile
12.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 7.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BERTAGNA, ANGELA MARIE - Prosecution Strategy Guide

Executive Summary

Examiner BERTAGNA, ANGELA MARIE works in Art Unit 1637 and has examined 687 patent applications in our dataset. With an allowance rate of 32.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner BERTAGNA, ANGELA MARIE's allowance rate of 32.8% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BERTAGNA, ANGELA MARIE receive 2.49 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BERTAGNA, ANGELA MARIE is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +54.6% benefit to allowance rate for applications examined by BERTAGNA, ANGELA MARIE. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 13.8% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 28.4% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 25.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 29% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 60.0% of appeals filed. This is in the 35% percentile among all examiners. Of these withdrawals, 77.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 61.8% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 71% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.1% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.